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OL-045 CpG DNA can enhance speciﬁc immune
responses in mice immunized with recombinant
hepatitis B surface antigen and hepatitis B
vaccine
P. He1 *, X.C. Zhang1, Z.Y. Hu1, X.T. Wang2, Z.L. Liang1.
1National Institutes for Food and Drug Control, 2William
A. Hinton State Laboratory Institute; Boston, USA
Background: Recently, studies showed that bacterial
DNA and synthetic non-methylated CpG containing
Oligonucleotide (CpG-ODN) can stimulate the immune
response, promoting the proliferation and differentiation
of immune cells.
Methods: BW006 (CpG-ODN) was used as an adjuvant for
recombinant HBsAg to immunize 6- to 8-week-old female
BALB/c mice with or without aluminium for different
dosages. The production of HBsAb, CD80 and CD86 from
dendritic cells were analyzed and compared for the
performance of immunization.
Results: BW006 dose dependant co-stimulation effect of
HBsAb serum conversion on regular HBV vaccine (containing
aluminium adjuvant) was seen between the ranges of 1.25
mg to 20 mg. Mice vaccinated with 20 mg BW006 and vaccine
showed the highest concentration of antibody production.
5 20 mg BW006 had the best co-stimulation effect of HBsAb
serum conversion for mice vaccinated with recombinant
HBsAg. 20 mg BW006 increased the positive proportion
(15.14% for BW006 alone and 15.84% for BW006 and 4 mg
recombinant HBsAg) and ﬂuorescent intensity (139.86 for
BW006 alone and 158.67 for BW006 and 4 mg recombinant
HBsAg) of surface molecule CD80 expression in leucocyte
cells. The same trend was seen in CD86, in which positive
expression proportion almost doubled in groups with BW006
compared with that in the control group (52.12% vs. 27.37%)
or in 4 mg recombinant HBsAg injection alone group (54.09%
vs. 28.36%). The ﬂuorescent intensity of CD86 expression
also increased with BW006 compared with that of the
control group (292.68 Vs. 213.78) or of HBsAg alone group
(299.35 Vs. 211.78).
Conclusions: Our results conﬁrmed the adjuvant effect of
BW006 for HBsAg in the mouse model. The activation of
CD80 and CD86 molecules by CpG-ODN might be part of the
mechanism of T/B cells coordination and the enhancement
of recombinant HBsAg induced immune response.
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Background: DC-SIGN is known to be a novel receptor
on the human dendritic cells, and the promoter region
mutation of DC-SIGN have a broad rang of inﬂuence with
some pathogens, for example human immunodeﬁciency virus
type 1 (HIV-1), hepatitis C virus (HCV) and mycobacterium
tuberculosis. But it is poorly understood in hepatitis B virus
(HBV). To investigate whether there is mutation in DC-
SIGN promoter region in patients with chronic hepatitis B
(CHB) and healthy persons previously infected with HBV for
exploring the relationship between the mutation in DC-SIGN
promoter region and HBV.
Methods: The studied population was composed of two
cohorts of 47 CHB patients and 20 healthy persons previously
infected with HBV. The mutation in DC-SIGN promoter
region detection was performed by using polymerase chain
reaction, single-stranded conformational polymorphism and
heteroduplex analysis, cloning, sequencing and aligning with
the published DC-SIGN promoter sequence.
Results: The characteristic mutation within DC-SIGN
promoter region in HBV infection individuals was observed.
In DC-SIGN promoter region, four hot spot mutations located
in positions 139, 142, 222, and 336 were observed in
CHB patients, but only one spot mutation located in position
139 was observed in healthy persons previously infected
with HBV. The 336C which was absent in healthy persons
previously infected with HBV was shown in 11 CHB patients
(23.40% (11/47)). The 139T was far more frequent in
healthy persons previously infected with HBV (100% (20/20))
than in CHB patients (34.04% (16/47)).
Conclusions: Perhaps, in DC-SIGN promoter region, the
336C is a genetic risk factor for developing CHB, but the
139T may be associated with protection against HBV.
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Background/Aim: Adefovir dipivoxil (ADV) has shown
efﬁcacy and safety in a broad range of populations with
chronic hepatitis B over 48 to 96 weeks. This study reports
the 144-week long-term efﬁcacy data with ADV treatment
in nucleoside-naive HBeAg-positive chronic hepatitis B.
Methods: Ninety-eight HBeAg-positive patients who had
never received nucleoside treatment received 144-week
ADV10mg/d therapy. All patients had serum level of
HBV load over 105copies/ml and increased serum alanine
aminotransferase (ALT) level. Based on serum ALT levels
at baseline, all patients were divided into two groups,
A (48 patients with serum ALT level less than 200U/L) and
B (50 patients with ALT level more than 200U/L). Serum
HBV load was measured with quantitative real-time-PCR.
ALT activity, HBeAg, anti-HBe-antibodies, HBVDNA level in
serum were evaluated at baseline, week 12, 24, 48, 96 and
144 and during therapy.
Results: After 24 weeks of therapy, mean reduction of
HBVDNA level, the percentage of patients with HBVDNA
lower than 5log10 copies/ml and the percentage of patients
with HBVDNA level decrease of more than 2log10 copies/ml
in group B were signiﬁcantly higher than those in group
A (P < 0.05, respectively). At the end of 24, 48, 96 and
144 weeks, the patients in group B had higher rates of
undetectable serum HBVDNA levels and ALT normalization
than those in group A (P < 0.05, respectively). HBeAg
seroconversion rate was signiﬁcant hihger in group B than
those in group A (P < 0.05). There was no evidence of adverse
effect in patients treated for up to 144 weeks.
Conclusions: ADV is an effective treatment option for
nucleoside-naive patients with HBeAg-positive chronic
hepatitis B, especially for those with high serum ALT levels
at baseline. Adefovir dipivoxil treatment through 144 weeks
was well tolerated and resulted in continued beneﬁt for
patients with HBeAg-positive chronic hepatitis B.
